NCT02006888View on ClinicalTrials.gov

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
InflammationCataracts
Interventions
DRUG

IBI-10090

DRUG

Placebo

Placebo

Trial Locations (1)

93534

Hull Eye Center, Lancaster

Sponsors
All Listed Sponsors
lead

ICON Bioscience Inc

INDUSTRY